Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune)

N/A

Report date: 2026/03/19 16:46:57

Base Information

Drug NameAnti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune)
Drug Alias Name抗CD3和抗HER2 BiTE的T细胞疗法
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsT cell surface glycoprotein CD3 inhibitors
TargetsT cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesUniversity Of MichiganHuazhong University Of Science And TechnologyUniversity Of Virginia Cancer Center +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesHuazhong University Of Science And TechnologyUniversity Of MichiganMedimmune Llc +[4] 
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A